Skip to main content
. Author manuscript; available in PMC: 2009 Nov 30.
Published in final edited form as: Nat Immunol. 2008 Jun 22;9(8):873–879. doi: 10.1038/ni.1627

Figure 3.

Figure 3

RvE1 improves lung inflammation, airway mucus and airway hyper-reactivity. Representative (n ≥ 3) lung tissue sections from day 21 mice given RvE1 (100 ng) or vehicle were obtained from fixed, paraffin embedded lung tissue, prepared and stained with hematoxylin and eosin (a-b) or Periodic Acid Schiff (PAS) (c-d). Original magnification ×100 and ×200 as indicated. Br; bronchus, V; vein. Arrowheads denote mucus (magenta) containing Goblet cells. e, RvE1 (200ng) (filled circles) or vehicle (open circles) was administered on days 18-20 and AHR to methacholine was measured on day 21. Lung resistance was measured by flexiVent, and the change in mean lung resistance was plotted as a percentage of baseline (PBS alone). f, Log ED200 (the effective dose of MCh required to increase mean lung resistance 200% from baseline) for RvE1 (black) and vehicle (white) exposed cohorts. Values represent the mean ± s.e.m. for n ≥ 6 in ≥ 3 independent experiments *, P <0.05 by one-way ANOVA.